Connect with us


Post Market Wrap | ResMed March quarter impacted by input cost inflation and higher freight costsPost Market Wrap |



This Post Market Wrap is presented by KOSEC – Kodari Securities

  • Revenue up by 12 percent to US$864 million and income from operations up by 5 percent to US$253 million
  • Revenue and income results miss Bloomberg consensus estimates
  • Gross margin down by 1.4 percent
  • Selling, general and administrative expenses up US$22 million, or 14 percent to US$182 million
  • Cash flow impacted by US$285 million ATO settlement
  •  Balance sheet remains strong with US$1.9 billion in cash and drawdown availability  
  • Management confident that incremental revenue growth will recover in FY23.  

ResMed Inc (‘ResMed’ or the ‘Group’) is a global medical device business that develops, manufactures, distributes and markets medical devices. ResMed  also develops cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing, chronic obstructive pulmonary disease and neuromuscular disease. Resmed’s comprehensive out-of-hospital software platforms are designed to assist caregivers and healthcare professionals keep people healthy in the home or care setting of their choice. The product suite includes air flow generators, diagnostic products and mask systems which are expected to help 250 million lives across 140 countries in 2025. 

Soft Gross Margin in March quarter FY22

ResMed increased revenue by 12 percent to US$864 million for the quarter, compared to the March 2021 quarter, and income from operations increased by 5 percent to US$253 million. Non-GAAP diluted earnings per share was up modestly from US$1.30 per share to US$1.32 per share. These numbers came in below market expectations, based on the important Bloomberg consensus estimates. The market was expecting stronger revenue growth, on the basis that ResMed would benefit from the recall of a competitor product in the US non-invasive ventilator market segment. This market share gain was less than anticipated by investors and can be attributed to ongoing semiconductor supply shortages. Semiconductors or micro-chips are an essential component of ResMed’s medical devices, including ventilators.  

The other disappointing aspect of the March quarter result was the 1.4 percent gross margin contraction to 56.8 percent at March 2022, from 58.2 percent at March 2021. The margindecline is attributable to higher freight and manufacturing costs, partially offset by an increase in average selling prices. A US$12/Euro12 device surcharge introduced in January 2022 has not been enough to offset the cost inflation and higher freight imposts that have emerged since the onset of the global COVID pandemic. Selling, general and administrative expenses increased by 14 percent to US$182 million, compared to the March 2021 quarter.This is an increase of US$22 million from a year ago. Clearly ResMed has not been able to avoid the input cost inflation pressures faced by manufacturers in all parts of the world in recent times.

US$285 million ATO settlement impacts cash flow

Cash from operating activities of US$272 million, for the 9 months to 31 March 2022, represents a decline of US$238 million from US$510 million generated in the previous corresponding 9 months.  The significant decline is primarily due to a US$285 million cash settlement with the Australian Taxation Office in the March quarter. This is the final instalment due to the ATO and follows payments of US$97 million in prior reporting periods, bringing the total amount to US$382 million. The settlement relates to transfer pricing irregularities between 2009 and 2018. The profit impact had previously been recognised in the prior financial year.  

ResMed retains a strong balance sheet and at 31 March had US$1.6 billion available for drawdown plus cash and cash equivalents of US$295 million. 

Looking Ahead

Management continues to refer to the extraordinary demand for sleep and respiratory care products around the globe with double-digit top line revenue growth expected for respiratory care products and high single-digit growth in its software-as-a-service business segment.

Despite the industry-specific and macro-economic environment uncertainty in recent times, demand from patients and healthcare providers remains resilient. Management remainsconfident that as supply chain logistical constraints, including semiconductor component shortages are overcome, lost incremental revenue will be recovered in FY23 and beyond.

This Post Market Wrap is presented by Kodari Securities, written by Michael Kodari, CEO at KOSEC.

"Michael Kodari is one of the world's most consistent, top performing investor. A philanthropist and one of the prominent experts of the financial markets, he has been referred to as ‘the brightest 21st century entrepreneur in wealth management' by CNBC Asia and featured on Forbes. Featured on TV as the "Money Expert", on the weekly Sunday program "Elevator Pitch", he is recognised internationally by governments as he was the guest of honour for the event "Inside China's Future", chosen by the Chinese government from the funds management industry, attended by industry leaders, when they arrived in Sydney Australia, on April 2014. Michael and George Soros were the only two financiers in the world invited and chosen by the Chinese government to provide advice, and their expertise on Chinese government asset allocation offshore. With a strong background in funds management and stockbroking, Michael has worked with some of the most successful investors and consulted to leading financial institutions. He was the youngest person ever to appear on the expert panel for Fox, Sky News Business Channel at the age of 25 where he demonstrated his skillset across a 3 year period forming the most consistent track record and getting all his predictions right over that period. Michael writes for key financial publications, is regularly interviewed by various media and conducts conferences around the world."

Continue Reading


Debt limit dispute: Will America default?



Can U.S. lawmakers agree on the debt limit before the fast approaching deadline to avoid default?

The executive branch and Congress are trying to strike a deal about the debt limit as the country marches closer to defaulting.

But can President Joe Biden and Republicans come to an agreement on fiscal policy in time?

The federal government could run out of money as early as June 1. Without borrowing more there is a risk that the United States will begin defaulting on its financial obligations.

Negotiations between Speaker Kevin McCarthy and President Joe Biden at the White House continue as lawmakers are staring down a swiftly approaching deadline.

The Treasury has been warning that the government would likely default on some bills in June if Congress does not raise the debt ceiling.

Democrats have insisted on raising the debt limit without preconditions. But Republicans say President Biden and the Democrats are playing Russian roulette with America’s economy after a two-year spending binge that brought 40-year high inflation and pushed the nation’s debt to over $31-trillion.

While both sides have agreed that action is needed to reduce the deficit—each have extremely different ideas about how to do it.

Republicans are looking to cut spending levels, while Democrats have called to increase tax revenue from the ultra-wealthy and large corporations.

So, can Washington D.C. politicians broker a deal and prevent the American economy from falling off a cliff?

Mitch Roschelle, Managing Director at Madison Ventures and a Visiting Research Fellow at the University of San Diego School of Business joined us to discuss. #U.S. Politics #Mitch Roschelle #debt ceiling #Capitol Hill #Washington D.C.

Continue Reading


Qantas leadership change takes full flight as airfares skyrocket



The next CEO of Australia’s high-profile airline, Qantas has a huge task ahead

After the long reign of her predecessor Alan Joyce, Vanessa Hudson inherits an airline with some key challenges ahead.

The challenges facing any CEO at the moment are high. Rising costs, tough competition, and cash-strapped customers are all part of the package when it comes to running an airline.

Qantas is one of the world’s most famous airlines.

At the height of the pandemic, the company’s results see-sawed.

However, it survived in part due to the actions of CEO Alan Joyce, and his right-hand CFO Vanessa Hudson.

Now, Alan Joyce is stepping down and Vanessa Hudson beat a field of 40 contenders for his job.

While Alan Joyce kept shareholders happy in recent times, some analysts believe he skimped on capital expenditure, leaving a multi-billion dollar hit to the new CEO.

Continue Reading


Why aren’t more U.S. banks failing?



The U.S. has witnessed one of the biggest bubbles of the past 100 years

Three U.S. banks have collapsed in a matter of months.

It could spell trouble for the world’s biggest economy as inflation soars.

It is part of a phenomenon known as an economic bubble, where current asset prices exceed their intrinsic valuation.

Silicon Valley Bank and Signature Bank are among those to fall apart.

Gregory Becker is the former CEO of the collapsed SVB, who says he’s “truly sorry” for what’s happened.

He says the bank was responsive to regulator concerns about managing risk and working to address issues.

Governments are grappling with the most rapid increase in interest rates across four decades. #featured #business #politics #banking

Continue Reading
Live Watch Ticker News Live

Trending Now

Copyright © 2023 The Ticker Company PTY LTD